

AMENDMENT

In the Claims:

Please amend Claims as follows:

1. (Cancelled)
2. (Previously Amended) The pharmacological agent of claim 17 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.
3. (Original) The pharmacological agent of claim 2 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.
- 4.-5. (Cancelled)
6. (Previously Amended) The pharmaceutical agent of claim 17 further comprising a pharmaceutically acceptable carrier, diluent or excipient.
7. (Cancelled)
8. (Currently Amended) A method of treating ~~an amyloid~~ Alzheimer's disease or Type II diabetes in a patient, comprising the step of administering to the patient a therapeutically effective amount of a combination of Ginkgo Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Ginseng, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12 or cobalamin, and Choline.
9. (Original) The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered orally.
10. (Original) The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered by aerosol spray.

11. (Original) The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered in a parenterally injectable or infusible form.
12. (Cancelled)
13. (Previously Amended) The pharmacological agent of claim 19 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.
- 14.-15. (Cancelled)
16. (Currently Amended) A method of treating ~~an amyloid~~ Alzheimer's disease or Type II diabetes in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Bilberry, Dong Quai and Aloe Vera, and a therapeutically effective amount of one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1.
17. (Currently Amended) A pharmacological agent comprising a therapeutically effective amount of a combination of Gingko Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Ginseng, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating ~~an amyloid~~ Alzheimer's disease or Type II diabetes in a patient.
18. (Cancelled)
19. (Currently Amended) A pharmacological agent comprising a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in

combination with a therapeutically effective amount of one or more substances selected from the group consisting of Dong Quai, Bilberry and Aloe Vera, and a therapeutically effective amount of one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating an amyloid ~~Alzheimer's disease~~ or Type II diabetes in a patient.

20. (New) A composition comprising a combination of plant matter from Gingko Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, further in combination with one or more substances selected from the group consisting of Ginseng, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline.

21. (New) A composition comprising plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with one or more substances selected from the group consisting of Dong Quai, Bilberry and Aloe Vera, and further comprising one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl or vitamin B1

22. (New) A pharmacological agent comprising a therapeutically effective amount of a combination of Gingko Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Ginseng, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in reducing, disrupting, dissolving, inhibiting, eliminating or preventing amyloid fibrils in a subject.

23. (New) A pharmacological agent comprising a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically

effective amount of one or more substances selected from the group consisting of Dong Quai, Bilberry and Aloe Vera, and a therapeutically effective amount of one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in reducing, disrupting, dissolving, inhibiting, eliminating or preventing amyloid fibrils in a subject.

24. (New) The pharmaceutical agent of claim 17 wherein the therapeutically effective amount of plant matter has an *in vitro* amyloid inhibitory activity or efficacy greater than 50%.

25. (New) The pharmaceutical agent of claim 19 wherein the therapeutically effective amount of plant matter has an *in vitro* amyloid inhibitory activity or efficacy greater than 50%.